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Purpose
The genetic alteration of the janus kinases (JAKs), non-receptor tyrosine kinase, is related to
the development of human cancers. However, little is known about how the sequence
variation of JAK3 contributes to the development of lung cancer. This study investigated
whether polymorphisms at the promoter region of the JAK3 gene are associated with the risk
of lung cancer in the Korean population.
Materials and Methods
A total of 819 subjects, including 409 lung cancer patients and 410 healthy controls were
recruited. The SNaPshot assay and polymerase chain reaction-restriction fragment length
polymorphism analysis were used, and logistic regression analyses were performed to
characterize the association between polymorphisms of JAK3and lung cancer risk. 
Results
Three polymorphisms (-672 GĥA, +64 AĥG and +227 GĥA) of JAK3 were analyzed for
large-scale genotyping (n=819). Statistical analyses revealed that polymorphisms and
haplotypes in the JAK3 gene were not significantly associated with lung cancer.
Conclusion
JAK3 gene was not significantly associated with the risk of lung cancer in the Korean
population.
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Introduction
Lung cancer is the leading cause of cancer-related death, accounting
for one third of all deaths from cancer worldwide [1,2] and ranks the
second highest in incidence in Korea [3]. Lung cancer therapies rarely
cure, and the overall 5-year survival rate is still only 15% [2]. More-
over, lung cancer is often diagnosed after the appearance of clinical
symptoms, which may be due to primary disease, metastasis or
formation of neoplasm [4]. Even though the necessity to reduce theWonbeak Yoo, et al_The Polymorphisms of JAK3 Gene and Lung Cancer Risk
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incidence of lung cancer and improve the poor current outcome is very
important, the molecular mechanisms for lung cancer development
have not been well characterized.
Tyrosine kinase (TK) growth factor receptors on the cell membrane
are good targets in cancer therapy because signals from these receptors
promote cell growth and survival [5]. They play a critical role in a wide
range of biological processes, including embryonic development,
organism growth, angiogenesis, synaptic plasticity and oncogenesis
[6]. Janus tyrosine kinases (JAKs) are one of eleven mammalian non-
receptor TK families that are essential mediators of cellular signaling
through cytokine receptors. JAK activates signal transducers and
activators of transcription (STAT) factors to dimerize and translocate
into the nucleus, which will initiate the transactivation of target genes.
This pathway is crucial to hematopoiesis, immune response,
oncogenesis, and proliferation [7,8]. The association of JAK with cell
growth and proliferation, and its critical role in tumorigenesis of cancer
has been investigated previously [9,10]. Furthermore, JAK genes are
often mutated in human cancers, suggesting that JAK3 mutations may
to be functional and contribute to cancer development including
leukemia, breast, and lung cancer [11,12]. Also, in human colorectal
cancer, JAK3 expression had a significant association with tumor
differentiation, pathological T-stage, and tumor-node-metastasis
(TNM) stage [13]. It was reported that the JAK3/STAT3 signaling
pathway plays an important role in the pathogenesis of human colon
cancer by promoting cell survival and counteracting apoptotic cell
death [13,14]. 
Despite its potential roles in cancer development, there are no
comprehensive genetic studies to date on the correlation between JAK3
and lung cancer incidence. In this study, we evaluated the relationship
between JAK3 polymorphisms and clinic pathological parameters in
Korean lung cancer patients by analyzing genotypes and haplotypes.
Our data showed that JAK3 polymorphisms and haplotypes are not
significantly associated with lung cancer risk in the Korean population.
Materials and Methods
1 Subjects
Blood samples were collected between August 2001 and June 2006
from 819 subjects, including 409 lung cancer patients and 410 healthy
controls. Lung cancer patients were recruited from the patient pool at
the Genomic Research Center for Lung and Breast/Ovarian Cancer
and Inha University Medical Center. On the other hand, control sub-
jects were randomly selected from the Cardiovascular Genome Center,
Genomic Research Center for Allergy and Respiratory disease and
Keimyung University Dongsan Medical Center. The histological
classification and staging of all patients was performed by pathological
evaluation and the clinical or pathological stages of lung cancer at the
time of diagnosis were determined by reviewing the medical records
based on the TNM system.
Each patient and control subject completed detailed questionnaires
covering diet, smoking status, drinking status, lifestyle and medical
history, with assistance from a trained interviewer. For the smoking
status of the subjects, any subject who reported smoking at least once
on a daily basis was considered a smoker for the purpose of this study.
All study subjects provided written consent, and were approved for the
study protocol by the Institutional Review Board.
2  DNA isolation and genotyping
Total genomic DNA was extracted using the PUREGENE blood
DNA purification system (Gentra, Minneapolis, MN), according to the
manufacturer s instructions. Purified genomic DNA was eluted in 50 Ǻ L
elution buffer and 50 ng of DNA was used for polymerase chain
reaction (PCR). After initial genotyping among 24 randomly selected
samples from lung cancer patients, we focused on polymorphisms in
the JAK3 promoter region. We analyzed the region spanning 2 Kb
upstream from the translation initiation site (primers shown in Appen-
dix 1). The positioning of polymorphisms, primer and probe designs
relative to the transcriptional start site of JAK3 were based on the
GenBank sequence (accession no. NT_011295). Single base extension
was performed using gene-specific primers according to the
manufacturer s protocol (ABI Prism SNaPshot multiplex system, PE
Applied Biosystems, Warrington, UK; Foster City, CA). A genotyping
assay based on the SNaPshot dNTP primer extension (PE Applied
Biosystems) and restriction fragment length polymorphism (RFLP)
methods were performed for genotyping of JAK3. Genotype study of
JAK3 polymorphisms (-672 GĥA and +227 GĥA) were performed
by the SNaPshot assay (primers shown in Appendix 2). Also, geno-
typing of +64 AĥG polymorphisms were carried out by PCR-RFLP,
which was done using a set of primers +64 AĥG, 5´-CTGGGTG
CAAAATTAGTTCCA-3´(sense), and 5´-CATCGCC AGCT
CTTACCTAGC-3´(antisense) to generate a 231 bp fragment. Each
PCR product (10 Ǻ L) was digested with 0.5 U of Msc1 according to
manufacturer instructions at 37 for 8 hours. Following that, the
digests were subjected to 2% agarose gel electrophoresis and stained
with ethidium bromide to visualize allele-specific fragments.
3 Statistical analysis
Allele frequencies, genotype frequencies, and departures of the
genotype distribution form Hardy-Weinberg equilibrium for each
polymorphism were analyzed using the chi-square test or Fisher’s exact
test. Pairwise linkage disequilibrium (LD) for calculating D’ and r
2was
evaluated as described previously [15]. Linkage disequilibrium (|D’|)
was calculated by the Haploview program ver. 3.2 (http://www.broad.
mit.edu/mpg/haploview). Genotype-specific risks were estimated as
odds ratios with associated 95% confidence intervals using uncon-
ditional logistic regression analysis ver. 8.02 (SAS Institute, Cary, NC)
and they were adjusted for age and sex. p-value of ģ0.05 was con-Cancer Res Treat. 2011;43(2):108-116
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sidered statistically significant. p-values were also calculated for multi-
ple testing using Bonferroni s inequality method.
Results
The demographics of the cases and controls enrolled in this study are
shown in Table 1. We screened the promoter region of the JAK3 gene
for polymorphisms in a small sample set of 24 lung cancer cases, and
found 8 different JAK3 polymorphisms, including five novel polymor-
phisms. Among the 8 polymorphisms, 3 polymorphisms (-672 GĥA,
rs6512226; +64 AĥG, rs7254346; and +227 GĥA, rs7250423) were
selected for large-scale genotyping, based on their frequencies (ĥ25%),
LD and haplotype tagging status (Table 2, Fig. 1). Genotype fre-
quencies for case and controls were in Hardy-Weinberg equilibrium.
Linkage disequilibrium coefficients (|D’|) between the polymorphisms
were calculated using the Haploview program. 
Three polymorphisms were used for haplotype construction. The
allelic frequencies of each polymorphism and haplotype were
compared between the patients and controls using logistic regression
models (Table 3). In genotype analyses, -672 GĥA, +64 AĥG, and
+227 GĥA were not associated risks of lung cancer in the overall and
all subgroup analyses. The subsequent analysis showed that haplotype
including 3 genotypes was not associated with an increased risk of lung
cancer overall. However, further haplotype analysis revealed that ha-
plotype 3 (+64A and +227A) was marginally associated with in-
creased lung cancer risk in females, non-smokers and non-drinkers
(Table 4). Other haplotypes including haplotype 1 (+64G and +227A),
haplotype 2 (+64A and +227G), and haplotype 4 (+64G and +227G)
remained not significant after stratifying by clinic pathological
parameters (data not shown). 
Discussion
In this study, we hypothesized that JAK3 polymorphisms were asso-
ciated with lung cancer risk and that these polymorphisms may play a
role as predictors of lung cancer. Here, we analyzed 3 polymorphisms
of JAK3 promoter region by using genomic DNA from representatives
of the Korean population. Our findings indicated no significant
association between polymorphisms of the JAK3 gene and lung cancer
risk. The small number of study subjects may have affected the lack of
association.
Accumulating evidence indicated that dysregulation of the JAK-
STAT signaling pathway caused cancers including lung cancer
[10,16]. Studies have also shown that the JAKs interact with other
well-known mitogenic pathways such as Raf/MEK signaling in the
pathogenesis of malignancies [17,18]. Nevertheless, most JAK3 stu-
dies focused on leukemias, immune related diseases and lymphomas
[11,19] and a relatively small number of studies were performed in
solid cancer [16,20]. Recently, it has been suggested that the JAK-
STAT pathway may be an effective target to control abnormal cell
proliferation in lung cancer or pulmonary fibrosis through neuregulin-1
activation [21]. Despite their potential importance, polymorphisms of
JAK3 in particular have not been examined. We therefore attempted to
investigate a possible association between polymorphisms of JAK3
promoter and risk of lung cancer. Our data suggested that some
haplotypes of JAK3 promoter were associated with an increased risk of
lung cancer in the Korean population. This study is, to the best of our
knowledge, the first report providing evidence for an association of the
JAK3 promoter polymorphism with lung cancer risk. 
Although cigarette smoking is considered one of the most important
risk factors of lung cancer, previous studies have suggested genetic
difference in epidemiologic characteristics such as non-smoking contri-
butes to the pathogenesis of lung cancer [22,23]. Also, the associations
between alcohol drinking and lung cancer risk have also been reported
[11,24]. In our previous study, we showed that polymorphisms of the
Her2 gene are associated with an increased susceptibility to lung cancer
in females, non-smokers, and non-drinkers in the Korean population
[15]. In the present study, haplotypes of the JAK3 gene increase the
susceptibility to lung carcinogenesis on females, non-smokers, and non-
drinkers. This suggests that genetic constitution of individuals is
important in determining their susceptibility to lung cancer [25].
Table 1. Baseline characteristics of the study population
Case Control
(n=409) (n=410)
p-value
Age at diagnosis (yr) 60.81 60.83 0.8428 
Sex Male 305 301 0.7058 
Female 104 109
Smoking status Smoker 290 147 0.0001
Non-smoker 108 162
Drinking status Drinker 193 139 0.3492 
Non-drinker 119 72
Table 2. Polymorphisms in the JAK3 gene identified in 24 lung
cancer patients
Loci Position SNP ID Allele frequency
-1,714 GĥC Promoter - G : C=0.896 : 0.104
-996 AĥC Promoter - A : C=0.896 : 0.104
-672 GĥA Promoter rs6512226 G : A=0.562 : 0.438
-570 AĥG Promoter  - A : G=0.979 : 0.021
-479 AĥG Promoter  - A : G=0.958 : 0.042
-196 GĥA Promoter  - G : A=0.958 : 0.042
+64 AĥG Promoter rs7254346 A : G=0.750 : 0.250
+227 GĥA Promoter rs7250423 G : A=0.750 : 0.250
Bold data indicates single nucleotide polymorphisms (SNPs) genotyped in a larger
population (n=819). JAK3, janus tyrosine kinase3. Wonbeak Yoo, et al_The Polymorphisms of JAK3 Gene and Lung Cancer Risk
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Conclusion
In this study, we identified 8 variations, including 5 novel
polymorphisms, in the JAK3 promoter from 819 Korean subjects. Our
data showed that haplotypes (-672 GĥA and +64 AĥG) are
marginally associated with the increased risk of lung cancer, parti-
cularly in subgroups of the Korean population. However, we con-
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Fig. 1. Map of polymorphisms, haplotypes, and linkage disequilibrium (LD) coefficients in janus tyrosine kinase3 (JAK3) gene. (A) The location
of 8 polymorphisms in the JAK3 gene on chromosome 19p13.1. Asterisks indicated polymorphisms that were genotyped in a larger population.
The frequencies of polymorphisms were based on sequencing data (n=24). The first base of the translation site was denoted as nucleotide +1. (B)
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cluded that no significant association existed between these JAK3
polymorphisms and lung cancer risk in the Korean population. 
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SNP PCR volume
Annealing Primer
temperature () Forward Reverse
-1,714 GĥC 10 Ǻ L PCR with Betaine 60 CAGGAAACAGCTATGACCGGCA TGTAAAACGACGGCCAG
TGACCACAGCTAAC TTAATCTGGAGCCACAGG
-996 AĥC 10 Ǻ L PCR with Betaine 60 CAGGAAACAGCTATGACCCC TGTAAAACGACGGCCAGTTGG
CAAGTCTCTGCATTTG TGATGCCTGTAATCC
-672 GĥA 10 Ǻ L PCR with Betaine 60 CAGGAAACAGCTATGACCTAA TGTAAAACGACGGCCAG
ACGAAGTCCCGCTCT TAGACAGGCTGCTGGAGA
-570 AĥG 10 Ǻ L PCR with Betaine 60 CAGGAAACAGCTATGACC TGTAAAACGACGGCCAGTA
TAAACGAAGTCCCGCTCT GACAGGCTGCTGGAGA
-479 AĥG 10 Ǻ L PCR with Betaine 60 CAGGAAACAGCTATGACCT GTAGACAGGCTGCTGGAGA
AAACGAAGTCCCGCTCT TGTAAAACGACGGCCA
-196 GĥA 10 Ǻ L PCR with Betaine 60 CAGGAAACAGCTATGACCC TGTAAAACGACGGCC
CCAACTCACACATGCTAC AGTATGCGCAATGACTCCTC
+64 AĥG 10 Ǻ L PCR with Betaine 60 CAGGAAACAGCTATGACC TGTAAAACGACGGCCA
CCCAACTCACACATGCTAC GTATGCGCAATGACTCCTC
+227 GĥA 10 Ǻ L PCR with Betaine 60 CAGGAAACAGCTATGACCC TGTAAAACGACGGCC
CCAACTCACACATGCTAC AGTATGCGCAATGACTCCTC
Appendix 1. Primer sequences for JAK3 variants screening
JAK3, janus tyrosine kinase3; SNP, single nucleotide polymorphism; PCR, polymerase chain reaction.
SNP Annealing temperature () Strand Primer Addtives
-672 GĥA 60 Forward ATCACCAGGCCTGGCTAATTTTCCT With betaine
+227 GĥA 55 Reverse GGATGCGAGTCTCGGCTCACGTCTG -
Appendix 2. Genotyping primer sequences for JAK3 variants screening
JAK3, janus tyrosine kinase3; SNP, single nucleotide polymorphism. 